Publications by authors named "D De Zeeuw"
Article Synopsis
- The CANPIONE study aimed to evaluate the effectiveness of canagliflozin, an SGLT2 inhibitor, in slowing the progression of chronic kidney disease (CKD) in participants with early-stage CKD and type 2 diabetes.
- In a trial involving 98 participants, those taking canagliflozin showed a significant reduction in urinary albumin levels and a slower decline in their estimated glomerular filtration rate (eGFR) compared to those receiving standard treatment.
- The study suggests that monitoring individual changes in eGFR slope could be a promising method for assessing the kidney-protective effects of new treatments in early CKD.
Background: In patients with advanced chronic kidney disease (CKD), the effects of initiating treatment with an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin-receptor blocker (ARB) on the risk for kidney failure with replacement therapy (KFRT) and death remain unclear.
Purpose: To examine the association of ACEi or ARB treatment initiation, relative to a non-ACEi or ARB comparator, with rates of KFRT and death.
Data Sources: Ovid Medline and the Chronic Kidney Disease Epidemiology Collaboration Clinical Trials Consortium from 1946 through 31 December 2023.
Aim: To explore the effect of canagliflozin on kidney and cardiovascular events and safety outcomes in individuals with type 2 diabetes and chronic kidney disease across geographic regions and racial groups.
Materials And Methods: A stratified Cox proportional hazards model was used to assess efficacy and safety outcomes by geographic region and racial group. The primary composite outcome was a composite of end-stage kidney disease (ESKD), doubling of the serum creatinine (SCr) level, or death from kidney or cardiovascular causes.
Key Points: Renin-angiotensin system inhibition was favorable for risk of kidney failure (compared with 0% decline with use of placebo or other agents) up to declines in eGFR of 13% over a 3-month period. Relation between eGFR decline after renin-angiotensin system inhibitor initiation and risk of outcomes was stronger in the first 2 years of follow-up and waned over time.
Background: Declines in GFR occur commonly when renin-angiotensin system (RAS) inhibitors are started.
Aim: This Phase I study evaluated the safety and early efficacy of an aldosterone synthase inhibitor (BI 690517) in people with diabetes and albuminuric chronic kidney disease.
Methods: Double-blind, placebo-controlled study (NCT03165240) at 40 sites across Europe. Eligible participants [estimated glomerular filtration rate ≥20 and <75 ml/min/1.